Accelerated Pharma, Inc. - FORM S-1/A - EX-23.1 - EXHIBIT 23.1 - December 2, 2016

Attached files

file filename
EX-10.23 - EXHIBIT 10.23 - Accelerated Pharma, Inc.v452898_ex10-23.htm
EX-10.24 - EXHIBIT 10.24 - Accelerated Pharma, Inc.v452898_ex10-24.htm
EX-10.22 - EXHIBIT 10.22 - Accelerated Pharma, Inc.v452898_ex10-22.htm
EX-10.21 - EXHIBIT 10.21 - Accelerated Pharma, Inc.v452898_ex10-21.htm
EX-10.20 - EXHIBIT 10.20 - Accelerated Pharma, Inc.v452898_ex10-20.htm
EX-10.19 - EXHIBIT 10.19 - Accelerated Pharma, Inc.v452898_ex10-19.htm
EX-10.18 - EXHIBIT 10.18 - Accelerated Pharma, Inc.v452898_ex10-18.htm
EX-10.17 - EXHIBIT 10.17 - Accelerated Pharma, Inc.v452898_ex10-17.htm
EX-10.15 - EXHIBIT 10.15 - Accelerated Pharma, Inc.v452898_ex10-15.htm
EX-10.8 - EXHIBIT 10.8 - Accelerated Pharma, Inc.v452898_ex10-8.htm
EX-10.3 - EXHIBIT 10.3 - Accelerated Pharma, Inc.v452898_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - Accelerated Pharma, Inc.v452898_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Accelerated Pharma, Inc.v452898_ex10-1.htm
EX-5.1 - EXHIBIT 5.1 - Accelerated Pharma, Inc.v452898_ex5-1.htm
EX-3.2 - EXHIBIT 3.2 - Accelerated Pharma, Inc.v452898_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - Accelerated Pharma, Inc.v452898_ex3-1.htm
S-1/A - S-1/A - Accelerated Pharma, Inc.v452898_s1a.htm

Exhibit 23.1

 

 

Independent Registered Public Accounting Firm’s Consent

 

 

We consent to the inclusion in this Registration Statement of Accelerated Pharma, Inc. on Form S-1 (Amendment #2) (File No. 333-214048) , of our report dated March 21, 2016, except for Note 1A, as to which the date is December 2, 2016, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the financial statements of Accelerated Pharma, Inc. as of December 31, 2015 and 2014 and for the years then ended, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.

 

 

/s/ Marcum llp

 

Marcum LLP

New York, NY

December 2, 2016